Fig. 3: Cell death is required for the IRF3 dimers formation and the IFNI expression.
From: Transglutaminase type 2-dependent crosslinking of IRF3 in dying melanoma cells
A Western blot analysis of caspase 3 expression in A375 cells treated with Z-VAD and doxorubicin for 16 h. GAPDH was used as loading control. B Western blot analysis of IRF3 expression in A375 cells treated with Z-VAD and doxorubicin for 16 h. GAPDH was used as loading control. (n = 3; means ± SEM; **p < 0.01). Western blot analysis showing IRF3 (C) and TG2 (D) protein expression in living and dying A375 cells upon doxorubicin treatment for 16 and 24 h. GAPDH was used as loading control. (n = 3; means ± SEM; **p < 0.01; **p < 0.00; *p < 0.05). E Densitometric analysis showing TG2 levels in living and dying A375 cells upon doxorubicin treatment for 16 and 24 h. F IFN-β mRNA levels, quantified by qPCR, in living and dying A375 cells treated with doxorubicin for 16 h and normalized with actin (n = 3; means ± SEM; **p < 0.01).
